With several new regimens nearing late-stage trials, a new generation of HIV antiretrovirals may soon be entering the marketplace.
The experimental drug ibalizumab, a monoclonal antibody, continues to effectively lower viral load in people with drug-resistant HIV through 48 weeks of treatment, as potential FDA approval nears.
A single-tablet combination D/C/F/TAF proved virologically noninferior to continuing a suppressive boosted protease inhibitor plus F/TDF at 48 weeks in the phase 3 randomized Emerald trial.
Highlights of major findings on new antiretroviral therapies, including data on long-acting injectable solutions and new combination treatments packed into a single pill.
HIV clinicians who have patients in declining health due to extensive HIV drug resistance may soon have a new lifesaving option. Ibalizumab, an HIV entry inhibitor in development, shows highly encouraging antiretroviral activity in the days after it ...
In this interview, Prema Menezes, Ph.D., discusses what motivates people living with HIV to enter into clinical trials and what stops those who have never participated from volunteering.
Each year we see new developments in HIV that improve the lives of those living with the disease and make it easier for providers to care for patients. We asked some of the leading experts what development this year they thought would have the biggest …
HIV treatment remains far from perfect, and there are still seats at the table available for improved antiretrovirals. Paul Sax, M.D., provides an update on several of the most noteworthy candidates currently in development.